Danish drugmaker Novo Nordisk (NVO) reported fourth quarter and full year 2024 earnings Wednesday, beating Wall Street's expectations and bumping its stock up more than 4% at market open.

Novo Nordisk's CEO is not worried about blockbuster semaglutide drugs being added to Medicare drug pricing negotiations this ...

With sales of Novo Nordisk’s obesity blockbuster Wegovy more than doubling in 2024 ... previously led to supply constraints for both products, though Novo appears to have largely rounded ...

Ozempic sales increased 12% to 33.85 billion Danish kroner, and Wegovy sales more than ... notifications across several products and geographies. Novo Nordisk is investing in internal and external ...

And the deal will result in a hit of $1.26 billion this year from debt financing. Injection pens and boxes of Novo Nordisk's weight-loss drug Wegovy are shown in this photo illustration in Oslo, ...

Novo Nordisk (NVO ... just had prices set for some of its insulin products in the past year. And the inclusion of the semaglutide drugs — Wegovy for weight loss and Ozempic for diabetes ...

Revenues from weight loss injection medication Wegovy more than ... economy ministry cited Novo Nordisk's production and exports for raising its gross domestic product growth forecast for 2024 ...